| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary molecular target of Midecamycin acetate is the bacterial 50S ribosomal subunit. It binds to the 23S rRNA component of the 50S subunit, inhibiting protein synthesis by blocking the translocation step of peptide chain elongation. This leads to inhibition of bacterial growth and cell death. The compound is bacteriostatic at low concentrations and bactericidal at high concentrations.
|
|---|---|
| ln Vitro |
In vitro, Midecamycin acetate demonstrates antibacterial activity against a range of gram-positive bacteria including Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae, as well as Mycoplasma species. MIC values typically range from 0.1 to 6.25 μg/mL. The compound is also active against some gram-negative bacteria including Haemophilus influenzae.
|
| ln Vivo |
Miocarcin (facial, once daily for 26 weeks) has a maximum non-toxic dose level of 250 mg/kg in cosmetic and feminine combinations (Wistar, SPF, 5 weeks of age).
In vivo, Midecamycin acetate is used for the treatment of respiratory tract infections, skin and soft tissue infections, and other bacterial infections. It is administered orally and achieves good tissue penetration, particularly in the lungs and soft tissues. The compound is well-tolerated and has been used effectively in both adult and pediatric patients. |
| Enzyme Assay |
For MIC determination, broth microdilution or agar dilution methods are used. Bacterial cultures are grown in appropriate media, and Midecamycin acetate is added at various concentrations (typically 0.03-128 μg/mL). After incubation at 35°C for 16-20 hours, the lowest concentration inhibiting visible bacterial growth is recorded as the MIC.
|
| Cell Assay |
For in vitro cell assays, bacterial cells are treated with Midecamycin acetate, and protein synthesis is measured by incorporation of radiolabeled amino acids. For mechanistic studies, ribosome binding assays are performed using purified 50S subunits and radiolabeled macrolide.
|
| Animal Protocol |
For in vivo studies, animal models of infection (e.g., mouse pneumonia or skin infection models) receive Midecamycin acetate by oral gavage. Bacterial burden in target organs is quantified by colony counting. Pharmacokinetic parameters are determined by measuring plasma and tissue drug concentrations by HPLC or LC-MS/MS.
|
| References | |
| Additional Infomation |
Miocadycin is a macrolide antibiotic. It is listed in the Japanese Pharmacopoeia and is available for clinical use in Japan. It is effective against a variety of Gram-positive and Gram-negative bacteria and can be used to treat upper respiratory tract infections, lower respiratory tract infections, and genitourinary tract infections, or as an alternative to erythromycin.
|
| Molecular Formula |
C45H71NO17
|
|---|---|
| Molecular Weight |
898.04200
|
| Exact Mass |
897.472
|
| CAS # |
55881-07-7
|
| Related CAS # |
55881-07-7 (acetate);35457-80-8;
|
| PubChem CID |
5282188
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2 g/cm3
|
| Boiling Point |
878.7ºC at 760 mmHg
|
| Melting Point |
~220° (with coloration)
|
| Flash Point |
485.2ºC
|
| Index of Refraction |
1.524
|
| LogP |
3.909
|
| tPSA |
218.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
63
|
| Complexity |
1590
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@H]3C[C@](OC(C)=O)(C)[C@@H](OC(CC)=O)[C@H](C)O3)[C@@H](C)O2)[C@@H](OC)[C@H](OC(CC)=O)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C1 |c:55,t:53,&1:3,4,6,7,9,13,15,17,23,29,32,35,38,48,55,60|
|
| InChi Key |
GQNZGCARKRHPOH-RQIKCTSVSA-N
|
| InChi Code |
InChI=1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1
|
| Chemical Name |
[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetyloxy-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4-acetyloxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1135 mL | 5.5677 mL | 11.1354 mL | |
| 5 mM | 0.2227 mL | 1.1135 mL | 2.2271 mL | |
| 10 mM | 0.1114 mL | 0.5568 mL | 1.1135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.